About Visterra
Visterra is a Healthcare company based in Cambridge (United States) founded in 2007 by Ram S, and was acquired by Otsuka in July 2018. Visterra has raised $116.17 million across 7 funding rounds from investors including Merck, ARE and Serum Institute of India. The company has 79 employees. Visterra offers products and services including Sibeprenlimab, VIS171, and VIS513. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its legal entity is Visterra Inc. Its competitors include Moderna, Adaptive Biotechnologies and MacroGenics; 3 of its 3 listed competitors have raised funding.
Company details
Developer of monoclonal antibodies against infectious diseases. The companys technology is powered by computational tools and techniques, the core of which is Atomic Interaction Network (AIN) analysis, which uniquely identifies an area, or epitope, on the target site that is fundamental to its structure and function. The lead product candidate, VIS410, is a broad-spectrum human monoclonal antibody for the prevention and treatment of both seasonal and pandemic influenza. The companys second product candidate, VIS513, is a human monoclonal antibody for the treatment of dengue that has been shown to broadly neutralize all four dengue virus serotypes.
- Headquarters Cambridge, United States
- Employees 79
- Founders Ram S
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website visterrainc.com
- Social LinkedIn Instagram
- Acquired by Otsuka (Jul 2018)
- Legal Name Visterra Inc
Products & Services of Visterra
Visterra offers a comprehensive portfolio of products and services, including Sibeprenlimab, VIS171, and VIS513.
Investigational therapy for IgA nephropathy treatment in clinical trials.
Early-stage development for immune-mediated disease therapies.
Pipeline program targeting hard-to-treat diseases through biologics.
Funding Insights of Visterra
Visterra has successfully raised a total of $116.17M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $46.7 million completed in October 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $116.17M
- Total Rounds 7
- Last Round Series C — $46.7M
- First Round $2.04M
(Feb 2008)
- Investors Count 16
All 7 funding rounds of Visterra with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2017 | $46.7M | Series C | – | Serum Institute of India, CTI Life Sciences Fund | |
| Sep 2016 | $149,990 | Grant | – | – | |
| Oct 2014 | $30M | Series B | – | Merck, Vertex Ventures HC | |
| Dec 2013 | $34.23M | Series A | – | Polaris Partners, Lux Capital | – |
| Sep 2010 | $6M | Debt – Conventional | – | – | – |
| Apr 2009 | $3.2M | Seed | – | Lux Capital, Flagship Pioneering | – |
| Feb 2008 | $2.04M | Seed | – | – | – |
17 investors in total: 17 institutional.
Investors in Visterra
Visterra has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, ARE and Serum Institute of India.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Stage agnostic VC firm investing primarily in the US | cycadvc.com | Santa Barbara, United States | ||
Early stage investments focused VC firm | acks.com | |||
Venture capital investments are made in life sciences companies. | ctisciences.com | Montreal, Canada | ||
Seed and early-stage therapeutics companies are invested in by MRLV. | mrlv.com | Cambridge, United States | ||
| vertexventureshc.com | ||||
Venture capital firm | omegafunds.com | Boston, United States | ||
An investment platform is provided for diverse sectors and geographies. | 1974 | temasek.com.sg | Singapore, Singapore | |
Seed and early-stage technology companies are funded by Lux Capital. | luxcapital.com | Menlo Park, United States |
Investor details for Visterra
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Visterra
74 people are tracked at Visterra (30 in leadership, 44 in team); the tracked headcount is 79.
| Name | Role | Group |
|---|---|---|
Ram S | Co-Founder | Leadership |
Kirk Rowley | Associate Director | Leadership |
Brian J.G. Pereira | President and CEO | Leadership |
Qing Huai | Associate Director | Leadership |
Susan Sloan | Vp, Nonclinical Development | Leadership |
Todd Curtis | Chief Financial Officer | Leadership |
Chris Kiefer | Chief Operating Officer | Leadership |
John Grossman | Head Of Human Resources | Leadership |
Jonathan Lonczak | Senior Director, Program And Alliance Management | Leadership |
Eric Gaffen | Head Of Talent Acquisition & Employee Experience | Leadership |
Jill Yarbrough | Vice President, Clinical Operations | Leadership |
Lee Andrews | Associate Director | Leadership |
Nicole Akramoff | Associate Director Clinical Operations | Leadership |
Jack O'Neil | Executive Director, Preclinical Development | Leadership |
Jean Bender | Vice President Pharmaceutical Sciences And Technology | Leadership |
Asher Schachter | Chief Medical Officer | Leadership |
Kathryn Ellis | Director, Research | Leadership |
Brandon J. Christensen | Senior Director | Leadership |
David Luciano | Executive Director, Finance & Controller | Leadership |
Greg Babcock | Chief Scientific Officer | Leadership |
54 more people are available in the full profile.
Complete people profiles for Visterra
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Visterra
4 dated milestones of Visterra across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Visterra is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series C, of $46.7M.
- Exit Acquired by Otsuka.
Competitors of Visterra
Visterra has 3 listed competitors in our database, 3 of them funded. They include Moderna, Adaptive Biotechnologies and MacroGenics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| macrogenics.com | 2000 | Rockville, United States | $126.02M | 339 | A biopharmaceutical company focused on cancer therapeutics development. |
Detailed competitors of Visterra
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Visterra
The website of Visterra (visterrainc.com) receives about 2.5K visits a month and ranks #6,988,741 among all websites worldwide, #6,851 in Biotechnology and Pharmaceuticals.
- Monthly visits2.5K
▲ 16.4% vs previous month
- Global rank#6,988,741
among all websites
- Category rank#6,851
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit2.0
- Average visit45 sec
- DevicesDesktop 45% · Mobile 55%
Websites whose visitors overlap most with Visterra. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
ir.sunesis.com | ir.sunesis.com | 100% | – | ||
infectiousdiseasenews.com | infectiousdiseasenews.com | 58% | – | ||
bjditan.org | bjditan.org | 58% | – | ||
svanova.com | svanova.com | 58% | – | ||
sidp.org | sidp.org | 58% | #3,041,688 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Visterra
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Visterra (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Visterra
Complete news archive for Visterra
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Visterra
Visterra was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Visterra is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Visterra is a funded company, having raised a total of $116.17M across 7 funding rounds to date. The company's 1st funding round was a Seed of $2.04M, raised on Feb 2008.
Visterra has 79 employees.
Developer of monoclonal antibodies against infectious diseases. The companys technology is powered by computational tools and techniques, the core of which is Atomic Interaction Network (AIN) analysis, which uniquely identifies an area, or epitope, on the target site that is fundamental to its structure and function. The lead product candidate, VIS410, is a broad-spectrum human monoclonal antibody for the prevention and treatment of both seasonal and pandemic influenza. The companys second product candidate, VIS513, is a human monoclonal antibody for the treatment of dengue that has been shown to broadly neutralize all four dengue virus serotypes.
Visterra's top competitors include Moderna, Adaptive Biotechnologies and MacroGenics.
Visterra offers Sibeprenlimab, VIS171, and VIS513.
Visterra has 17 investors. Key investors include Merck, ARE, Serum Institute of India, Otsuka, and Gates Foundation.
Visterra operates through Visterra Inc.
Yes. Visterra was acquired by Otsuka in July 2018.